Company Overview of Protein Sciences Corporation
Protein Sciences Corporation develops, manufactures, and commercializes vaccines and biopharmaceuticals for the prevention and treatment of various diseases. The company offers Flublok, a recombinant protein-based seasonal influenza vaccine; Panblok, a pandemic influenza vaccine; FluNhance that is used to enhance additive to influenza vaccines; and SARS (D3252), a Severe Acute Respiratory Syndrome vaccine that is used to elicit neutralizing antibodies to the virus. It also provides Baculovirus Expression Vector System, a platform technology used for the development of a range of vaccines and therapeutics, such as prophylactic vaccines, therapeutic vaccines, gene therapy, and biologic applica...
1000 Research Parkway
Meriden, CT 06450
Founded in 1983
Key Executives for Protein Sciences Corporation
Chief Executive Officer, President and Director
Chief Administrative Officer, Senior Vice President and Corporate Secretary
Senior Vice President of Manufacturing Operations
Senior Vice President of Quality
Compensation as of Fiscal Year 2016.
Protein Sciences Corporation Key Developments
Protein Sciences Corporation and Avanzcare Sign Exclusive Agreement for Distribution of Flublok® and Panblok® Influenza Vaccines to Middle East and North Africa
Sep 22 16
Protein Sciences Corporation and Avanzcare announced that they have signed an agreement designating Avanzcare as the exclusive distributor of Protein Sciences Corporation's proprietary Flublok® (seasonal) and Panblok® influenza vaccines and potentially other vaccines to be developed in the future for certain Middle East and North Africa markets. Under the terms of the agreement, Avanzcare will pursue registration of Flublok in all licensed countries and will initially purchase Flublok from Protein Sciences for distribution in the region. The MENA region represents about 6% of the total world population. This agreement dramatically expands the global footprint of Flublok and other Protein Sciences' vaccines.
Sinergium Biotech and Protein Sciences Corporation to Produce Zika Vaccine by 2018
Aug 26 16
Protein Sciences Corporation, Sinergium Biotech, and Mundo Sano, a private foundation with activities in Argentina, Spain, and Africa, have announced that their clinical testing of candidate Zika vaccines is progressing well and forecast that by 2018 they will have a Zika vaccine ready to launch in the market. The vaccine being developed is based on production of recombinant variations of the E protein from the Zika virus. Similar vaccine candidates produced at Protein Sciences against West Nile virus and Japanese encephalitis virus, which are close relatives of the Zika virus, have previously been shown to neutralise their respective targets in preclinical studies. The companies have focused on active discussions with additional strategic partners worldwide that could strengthen and rapidly advance the development programme.
Protein Sciences Corporation Announces Release of First Lots of Flublok® Influenza Vaccine
Aug 10 16
Protein Sciences Corporation announced that the FDA has approved and released the first lots of Flublok® influenza vaccine for distribution this season. Doses have been shipped and healthcare professionals and pharmacies that have pre-ordered Flublok should receive the vaccine this week. Flublok is approved for all people 18 and older and was recently shown in a clinical study of adults 50 and older to provide over 40% better protection against cell culture confirmed influenza compared to a flu vaccine made using embryonated hens' eggs the 60 – year old vaccine production technology. Flublok also offers a pure choice for vaccination as it is comprised of purified protein and lacks the unnecessary ingredients contained in other flu vaccines, such as influenza virus, antibiotics, preservatives, egg protein, gelatin or latex.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|